P I Industries Ltd Q2 FY2025 Concall Summary

Key Takeaways

• Growth guidance cut on channel destocking: FY25 revenue outlook reset to high single digits from double digits, as global agrochemical companies aggressively reduce working capital and inventory, slowing legacy molecule offtake.
• Margins surge on mix, not volume: Gross margin jumped 519 bps to 52% and EBITDA margin hit 28%, driven by a favourable shift toward new products, biologicals, and domestic branded formulations rather than operating leverage.
• Pharma hit by a customer bankruptcy: One innovator customer filed Chapter 11 in Q2, leaving inventory unsupplied and depressing pharma revenue and margins while development spend continued; the vertical remains a multi-year investment story.
• New products are the real growth engine: Molecules commercialized in the last three years grew 45%, while legacy molecules grew just 2-4%, validating the strategy of aggressive portfolio refresh.
• What to watch next quarter: Whether the pharma order book converts to a healthy H2 run-rate, the pace of inventory normalization in agchem exports, and any EBITDA contribution from the pharma vertical.

Growth Reset: Why Guidance Came Down

• Channel destocking, not demand destruction: Global agrochemical companies are rationalizing working capital and reducing inventory exposures, which is slowing offtake of PI's legacy molecules even as end-demand remains intact.
• Legacy vs. new product divergence: Legacy molecules grew only 2-4% while molecules commercialized in the last three years grew 45% on a lower base, confirming that the pain is concentrated in older products where customer inventories are elevated.
• H1 vs. H2 trajectory: AgChem exports grew 10-11% in H1 but are expected to decelerate to higher single digits in H2; domestic branded business is expected to deliver low double-digit growth in H2, partly offsetting the export slowdown.
• Inventory normalization is unpredictable: Management described a "wait-and-watch" situation where some customers signal a slowdown then suddenly demand urgent air shipments two months later; normalization could take another 2-3 quarters.
• High base compounds the optics: Last year's Q2 grew 24% and H1 grew 22%, making even solid absolute performance look softer on a YoY basis.

Rajnish Sarna: "We also witnessed some very interesting scenarios where we were indicated that there was a slowdown in specific product requirements, and then suddenly, two months later, we are air shipping products due to urgent requirements. So, you can imagine, there are different kinds of scenarios here and this is the reason I believe this is more a wait-and-watch kind of a situation, a transient situation because business fundamentals remain strong..."

Margin Performance: Mix-Driven Expansion

• Gross margin expanded 519 bps to 52%: The jump was driven by a favourable product mix in both export and domestic portfolios, with new products, biologicals, and branded formulations carrying higher realizations.
• EBITDA margin reached 28%, up 14% YoY: Management considers 26-27% sustainable for the core business, with the current quarter benefiting from mix tailwinds that may not fully repeat.
• New business margin drag: The health science and global biologicals businesses are still scaling and will take time to achieve a margin profile similar to the core agchem business.
• Cash flow conversion improved: Operating cash flow rose 20% on higher EBITDA and tighter working capital management; trade working capital days improved from 84 to 70, and inventory days from 63 to 50.

Rajnish Sarna: "We consider 26-27% margin to be sustainable, particularly for the core business that we are talking about here. It would, however, take us some time to scale up and achieve a similar kind of margin profile for the new businesses that we have invested, e.g., health science and global biological business."

Pharma Vertical: A Setback and a Long Build

• Customer bankruptcy hit Q2: One innovator customer filed Chapter 11 during the quarter; inventory meant for them was not supplied, which impacted both projected revenues and margins while development spend continued.
• Volume decline in H1, recovery expected: Pharma saw a volume reduction in the first half due to high inventories at innovators; volume is expected to pick up in Q3 and Q4 as order visibility translates into a healthier run-rate.
• Infrastructure build-out progressing: The Hyderabad R&D facility and Jaipur facilities are now operational; the Italy site has a key role placed and should be operational in Q1 FY26, completing back-integration.
• Revenue target of ₹250-275 crore by year-end: A new CDMO order and three new projects were added in the pharma business, though management declined to quantify their near-term revenue impact.
• Long-term ambition intact: Management expects the pharma venture to reach a "completely different level" in 3-4 years and make a meaningful contribution, but near-term EBITDA positivity remains uncertain.

Ramesh S.: "We certainly hope that the trend will begin even in H2, but I will be able to give you a lot more clarity as we go into Q4 next year. So, if you can just hold that thought as I push through."

New Product Engine and Portfolio Refresh

• New products grew 42% YoY in exports: This is the core growth driver, with six to seven molecules commercialized annually and the pace expected to be maintained.
• Four products commercialized for exports in H1: The full-year target is six to seven, with the next batch of molecules expected to maintain traction and enhance the portfolio mix.
• Domestic launches continue: Four new brands launched in H1, including PRESSEDO, DORITO, OSHEEN ULTRA, and SOLJU; three more scheduled for H2.
• Enquiry pipeline healthy: More than 50% of non-agchem enquiries are for innovator products, signalling future commercialization opportunities beyond the current portfolio.
• Biologicals portfolio grew 18% YoY: The acquisition of Plant Health Care, now completed, adds protein and peptide platform expertise to scale biological solutions globally.

Domestic Business: Volume-Led Recovery

• Branded products improved 7% with 12% volume growth: Pricing pressure across the industry was mitigated by product mix and working capital optimization.
• H1 volume growth of 9% despite only 3% reported growth: The gap reflects price corrections in old molecules; new introductions over the last 2-3 years are driving real consumption growth.
• Rabi season prospects are positive: Better water reservoir levels, adverse weather events now behind, and good momentum in chili, rice, pulses, fruits and vegetables support a constructive outlook.
• H2 domestic growth expected in low double digits: Driven by new brand launches and favourable agronomic conditions.

New Business Investments: Biologicals and Pharma

• Plant Health Care acquisition completed: The business brings top-tier expertise in protein and peptide platforms for agri-biologicals; management sees a path to \$100 million in revenue as "very much possible" given significant product potential.
• Profitability timeline is 2-3 years out: Plant Health Care will take time to scale before it starts contributing meaningfully to profitability.
• Pharma CAPEX is front-loaded: ₹100-125 crore planned for FY25, with roughly half that level expected next year; total company CAPEX guided at ₹800-900 crore for the year.
• Italy site back-integration nears completion: A key role has been placed and the facility should be operational in Q1 FY26, adding manufacturing capability for the pharma vertical.

Guidance & Commitments

Key Metrics